VanEck Biotech ETF
BBH

$180.78

0.57%

Market Cap: $461M

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

65.84% more ownership

Funds ownership: 35.85% [Q1] → 101.69% (+65.84%) [Q2]

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

2% more funds holding

Funds holding: 110 [Q1] → 112 (+2) [Q2]

12% less capital invested

Capital invested by funds: $162M [Q1] → $142M (-$19.9M) [Q2]

41% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 34

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BBH.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.

Should You Invest in the VanEck Biotech ETF (BBH)?

BBH: Buy Rating, As Tech Investors Look Beyond FAANG

Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. BBH is under-discovered compared to peers, offers potential for trend change in favor of biotech sector.

BBH: Buy Rating, As Tech Investors Look Beyond FAANG

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024

I'm on the hunt for ‘Strong Buy' biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024

Zacks Investment Research

Biotech ETF (BBH) Hits New 52-Week High

VanEck Biotech ETF BBH is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 21.4% from its 52-week low price of $142.51/share.

Biotech ETF (BBH) Hits New 52-Week High

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.

Should You Invest in the VanEck Biotech ETF (BBH)?

ETF Investors Indicate Active Strategies and Product Innovation Will Fuel the Industry's Continued Growth: BBH 2024 Global ETF Investor Survey

BOSTON--(BUSINESS WIRE)--As the ETF industry reaches a milestone of $12.71 trillion in global assets, the Brown Brothers Harriman 2024 Global ETF Investor Survey finds that investors plan to further increase their use of ETFs in the next year, while also expanding the number of ETF providers they invest with. Active ETFs, which have grown at a staggering 38.4%i annual rate over the past 10 years, will continue to be a focus for ETF investors as they seek downside protection while pursuing new a.

ETF Investors Indicate Active Strategies and Product Innovation Will Fuel the Industry's Continued Growth: BBH 2024 Global ETF Investor Survey

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

The VanEck Biotech ETF (BBH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

Should You Invest in the VanEck Biotech ETF (BBH)?

Why Biotech Stocks May Be Ready For A Recovery

Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery.

Why Biotech Stocks May Be Ready For A Recovery

Zacks Investment Research

Where Are Biotech ETFs Headed After Q4 Earnings?

Look into how Biotech ETFs performed after Q4 earnings.

Where Are Biotech ETFs Headed After Q4 Earnings?

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on 12/20/2011.

Should You Invest in the VanEck Biotech ETF (BBH)?

See News Rankings